title: Advances in mobilization for the optimization of autologous stem cell transplantation.
abstract: In autologous stem cell transplantation, mobilized peripheral blood has replaced the bone marrow as the preferred source of hematopoietic stem cells (HSCs). Because HSCs normally exist in the blood in very low numbers, the use of agents to "mobilize" HSCs from the marrow niche to the peripheral blood is essential for successful transplantation. Until recently, granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor were the only approved agents by the US Food and Drug Administration for use as peripheral blood stem cell (PBSC)-mobilizing agents in the United States, but G-CSF has become the gold standard. Unfortunately, some patients fail to mobilize sufficient numbers of PBSCs for transplantation in response to G-CSF with or without chemotherapy. Recently, a new agent, plerixafor (AMD3100) added to G-CSF has been approved to enhance PBSC mobilization. This review will discuss the current methodologies to improve hematopoietic stem cell mobilization.
authors: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-7680, USA. jmvose@unmc.edu
authors: Julie M
authors: JM
authors: Vose
authors: Anthony D
authors: AD
authors: Ho
authors: Bertrand
authors: B
authors: Coiffier
authors: Paolo
authors: P
authors: Corradini
authors: Issa
authors: I
authors: Khouri
authors: Anna
authors: A
authors: Sureda
authors: Koen
authors: K
authors: Van Besien
authors: John
authors: J
authors: Dipersio
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001596:Benzylamines; D002138:Calibration; D000080027:Cyclams; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods* / Q000592:standards / Q000639:trends*; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008954:Models, Biological; D011908:Rationalization; D033581:Stem Cell Transplantation / Q000379:methods / Q000592:standards*; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D007155:Immunologic Factors; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; C088327:plerixafor